Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT was written by Kaitsiotou, Helena;Keul, Marina;Hardick, Julia;Muehlenberg, Thomas;Ketzer, Julia;Ehrt, Christiane;Kruell, Jasmin;Medda, Federico;Koch, Oliver;Giordanetto, Fabrizio;Bauer, Sebastian;Rauh, Daniel. And the article was included in Journal of Medicinal Chemistry in 2017.Recommanded Product: 133232-56-1 This article mentions the following:
In modern cancer therapy, the use of small organic mols. against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies. The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clin. relevant RTK. KIT is targeted for cancer therapy in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). However, acquired resistance mutations within the catalytic domain decrease the efficacy of this strategy and are the most common cause of failed therapy. Here, we present the structure-based design and synthesis of novel type II kinase inhibitors to overcome these mutations in KIT. Biochem. and cellular studies revealed promising mols. for the inhibition of mutated KIT. In the experiment, the researchers used many compounds, for example, 3-Iodo-2-methylbenzoic acid (cas: 133232-56-1Recommanded Product: 133232-56-1).
3-Iodo-2-methylbenzoic acid (cas: 133232-56-1) belongs to iodide derivatives. Organoiodine compounds occur widely in organic chemistry, but are relatively rare in nature. In the chemical industry, alkyl iodides serve as excellent alkylating agents and, specifically, methyl iodide is used as a methylating agent in the synthesis of various pharmaceutical drugs.Recommanded Product: 133232-56-1
Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com